Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Jennifer describes a glofitamab plus Pola-R-CHP trial where two chemotherapy cycles before the bispecific produced almost no CRS, likely from debulking. But patients then received the bispecific at chemotherapy nadir, making febrile neutropenia a real challenge if phase 3 succeeds and the regimen is adopted.

Related Insights

The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.

When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.

Jennifer shows CRS timing differs by drug: glofitamab peaks at the first 2.5 mg step-up, epcoritamab at its first full dose, and mosunetuzumab at the third dose. Follicular lymphoma's extra epcoritamab step-up lowered high-grade CRS. Outpatient monitoring must match the exact agent and dose in practice.

Contrary to expectations, adding Tafasitamab and Lenalidomide to the R-CHOP regimen for diffuse large B-cell lymphoma resulted in only a marginal increase in toxicity. The rate of high-grade febrile neutropenia was only 3-4% higher, a pleasant surprise compared to previous combination trials.

Provocative data from a German study showed an 81% complete response rate in untreated, elderly DLBCL patients using a chemotherapy-free regimen of polatuzumab (an ADC), glofitamab (a bispecific), and rituximab. This challenges the decades-long R-CHOP chemotherapy backbone and points to a future of targeted frontline therapies.

Oncologists hypothesize that using the T-cell engager Tarlatumab after chemotherapy has reduced tumor volume may be a safer strategy. Real-world evidence suggests high tumor burden increases the risk of severe Cytokine Release Syndrome (CRS), so using chemotherapy to first cytoreduce the cancer could mitigate this toxicity.

Experts view R-mini-CHOP, the standard for older/unfit DLBCL patients, as a poor benchmark that urgently needs to be replaced. Promising chemo-free or chemo-light regimens, like the R-Polo-Glofitamab combination, are seen as the future, aiming to improve outcomes in this vulnerable population without harsh toxicities.

To mitigate the risk of severe Cytokine Release Syndrome (CRS) from bispecific antibodies in patients with high tumor burden, a debulking strategy is effective. Administering two initial cycles of chemotherapy dramatically reduces disease volume, leading to almost zero CRS when the bispecific is introduced, making the treatment much safer.

Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.

Using the bispecific antibody epcoritamab directly in CLL patients with active disease triggers severe cytokine release syndrome due to high circulating disease burden. Administering fixed-duration venetoclax beforehand debulks tumor load, resulting in significantly lower cytokine release syndrome rates while achieving high undetectable minimal residual disease responses.